PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
34028068-0	2021	Demethyleneberberine promotes apoptosis and suppresses TGF-beta/Smads induced EMT in the colon cancer cells HCT-116.	demethyleneberberine	0-20	transforming growth factor alpha	Homo sapiens	55-63
34735909-10	2021	In addition, the screened protoberberine, demethyleneberberine was found to exhibit prominent inhibitory activities against both LOX-5 and COX-2 enzymes, palmatine and berberine with moderate inhibitory activities.	demethyleneberberine	42-62	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	139-144
34735909-11	2021	Molecular docking analysis confirmed that demethyleneberberine could interact well with LOX-5/COX-2.	demethyleneberberine	42-62	prostaglandin-endoperoxide synthase 2	Rattus norvegicus	94-99
34229236-8	2021	Present article highlights new mechanistic insights through which DMB inhibits ROS/RNS, oxidative stress, mitochondrial dysfunctions and neuroinflammation such as NFkappaB, TNF-alpha, IL-6 and IL-8, cytokinin.	demethyleneberberine	66-69	nuclear factor kappa B subunit 1	Homo sapiens	163-171
34229236-8	2021	Present article highlights new mechanistic insights through which DMB inhibits ROS/RNS, oxidative stress, mitochondrial dysfunctions and neuroinflammation such as NFkappaB, TNF-alpha, IL-6 and IL-8, cytokinin.	demethyleneberberine	66-69	tumor necrosis factor	Homo sapiens	173-182
34229236-8	2021	Present article highlights new mechanistic insights through which DMB inhibits ROS/RNS, oxidative stress, mitochondrial dysfunctions and neuroinflammation such as NFkappaB, TNF-alpha, IL-6 and IL-8, cytokinin.	demethyleneberberine	66-69	interleukin 6	Homo sapiens	184-188
34229236-8	2021	Present article highlights new mechanistic insights through which DMB inhibits ROS/RNS, oxidative stress, mitochondrial dysfunctions and neuroinflammation such as NFkappaB, TNF-alpha, IL-6 and IL-8, cytokinin.	demethyleneberberine	66-69	C-X-C motif chemokine ligand 8	Homo sapiens	193-197
35597409-19	2022	RESULTS: Berberine, jateorhizine, coptisine, epiberberine, columbamine, demethyleneberberine, and berberrubine could significantly inhibit hOCT1 and hOCT2 activity.	demethyleneberberine	72-92	solute carrier family 22 member 1	Homo sapiens	139-144
34385092-0	2021	Demethyleneberberine induces cell cycle arrest and cellular senescence of NSCLC cells via c-Myc/HIF-1alpha pathway.	demethyleneberberine	0-20	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	90-95
34385092-0	2021	Demethyleneberberine induces cell cycle arrest and cellular senescence of NSCLC cells via c-Myc/HIF-1alpha pathway.	demethyleneberberine	0-20	hypoxia inducible factor 1 subunit alpha	Homo sapiens	96-106
34385092-5	2021	Flow cytometry and beta-Galactosidase Staining Kit were utilized to determine the efficiency of DMB on the cell cycle and cellular senescence of NSCLC cells.	demethyleneberberine	96-99	KIT proto-oncogene, receptor tyrosine kinase	Homo sapiens	47-50
34385092-12	2021	From the RNA-seq analysis, we found that DMB accelerates senescence through suppressing HIF-1alpha expression, which was further elucidated by overexpressing HIF-1alpha in NSCLC to reduce the inhibitory effect of DMB.	demethyleneberberine	41-44	hypoxia inducible factor 1 subunit alpha	Homo sapiens	88-98
34385092-12	2021	From the RNA-seq analysis, we found that DMB accelerates senescence through suppressing HIF-1alpha expression, which was further elucidated by overexpressing HIF-1alpha in NSCLC to reduce the inhibitory effect of DMB.	demethyleneberberine	41-44	hypoxia inducible factor 1 subunit alpha	Homo sapiens	158-168
34385092-12	2021	From the RNA-seq analysis, we found that DMB accelerates senescence through suppressing HIF-1alpha expression, which was further elucidated by overexpressing HIF-1alpha in NSCLC to reduce the inhibitory effect of DMB.	demethyleneberberine	213-216	hypoxia inducible factor 1 subunit alpha	Homo sapiens	88-98
34385092-12	2021	From the RNA-seq analysis, we found that DMB accelerates senescence through suppressing HIF-1alpha expression, which was further elucidated by overexpressing HIF-1alpha in NSCLC to reduce the inhibitory effect of DMB.	demethyleneberberine	213-216	hypoxia inducible factor 1 subunit alpha	Homo sapiens	158-168
34385092-13	2021	Furthermore, we also revealed that DMB decreases the expression of c-Myc, an up-stream protein of HIF-1alpha.	demethyleneberberine	35-38	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	67-72
34385092-13	2021	Furthermore, we also revealed that DMB decreases the expression of c-Myc, an up-stream protein of HIF-1alpha.	demethyleneberberine	35-38	hypoxia inducible factor 1 subunit alpha	Homo sapiens	98-108
34385092-14	2021	CONCLUSIONS: Taken together, we first report that DMB inhibits NSCLC progress through inducing cell cycle arrest and triggering cellular senescence by downregulating c-Myc/HIF-1alpha pathway.	demethyleneberberine	50-53	MYC proto-oncogene, bHLH transcription factor	Homo sapiens	166-171
34385092-14	2021	CONCLUSIONS: Taken together, we first report that DMB inhibits NSCLC progress through inducing cell cycle arrest and triggering cellular senescence by downregulating c-Myc/HIF-1alpha pathway.	demethyleneberberine	50-53	hypoxia inducible factor 1 subunit alpha	Homo sapiens	172-182
34028068-5	2021	Taken together, these findings suggested that DM-BBR could promote apoptosis and suppress TGF-beta/Smads induced EMT in the colon cancer cells HCT-116.	demethyleneberberine	46-52	transforming growth factor alpha	Homo sapiens	90-98
32145333-9	2020	The inhibitory activities of anemarrhenasaponin I, timosaponin AI, nyasol and demethyleneberberine were confirmed by the 5-LOX inhibitory assay for validating the reliability of affinity ultrafiltration approach and the computer-simulated molecular docking technique further clarified the possible mechanism of action between the active compounds and the 5-LOX active sites.	demethyleneberberine	78-98	arachidonate 5-lipoxygenase	Homo sapiens	121-126
32711021-0	2020	Highly efficient synthesis and monoamine oxidase B inhibitory profile of demethyleneberberine, columbamine and palmatine.	demethyleneberberine	73-93	monoamine oxidase B	Homo sapiens	31-50
32711021-4	2020	Furthermore, we found that DMB (IC50, 9.06 muM) inhibited the activity of monoamine oxidase B (MAO-B), an enzyme that deaminates dopamine and is particularly involved in the pathology of Parkinson"s disease.	demethyleneberberine	27-30	monoamine oxidase B	Homo sapiens	74-93
32711021-4	2020	Furthermore, we found that DMB (IC50, 9.06 muM) inhibited the activity of monoamine oxidase B (MAO-B), an enzyme that deaminates dopamine and is particularly involved in the pathology of Parkinson"s disease.	demethyleneberberine	27-30	monoamine oxidase B	Homo sapiens	95-100
32145333-9	2020	The inhibitory activities of anemarrhenasaponin I, timosaponin AI, nyasol and demethyleneberberine were confirmed by the 5-LOX inhibitory assay for validating the reliability of affinity ultrafiltration approach and the computer-simulated molecular docking technique further clarified the possible mechanism of action between the active compounds and the 5-LOX active sites.	demethyleneberberine	78-98	arachidonate 5-lipoxygenase	Homo sapiens	355-360
27900412-7	2017	RESULTS: In vivo, DMB significantly alleviated the weight loss and diminished myeloperoxidase (MPO) activity, while significantly reduced the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha), and inhibited the activation of NF-kappaB signaling pathway.	demethyleneberberine	18-21	myeloperoxidase	Mus musculus	78-93
31931366-0	2020	Demethyleneberberine attenuates concanavalin A-induced autoimmune hepatitis in mice through inhibition of NF-kappaB and MAPK signaling.	demethyleneberberine	0-20	mitogen-activated protein kinase 1	Mus musculus	120-124
31931366-4	2020	DMB significantly inhibited the infiltration of CD4+ T cell and Kupffer cell as well as the expression of inflammatory cytokines, such as TNF-alpha, IL-6, IL-1beta and IFN-gamma by ELISA and qPCR analysis.	demethyleneberberine	0-3	tumor necrosis factor	Mus musculus	138-147
31931366-4	2020	DMB significantly inhibited the infiltration of CD4+ T cell and Kupffer cell as well as the expression of inflammatory cytokines, such as TNF-alpha, IL-6, IL-1beta and IFN-gamma by ELISA and qPCR analysis.	demethyleneberberine	0-3	interleukin 6	Mus musculus	149-153
31931366-4	2020	DMB significantly inhibited the infiltration of CD4+ T cell and Kupffer cell as well as the expression of inflammatory cytokines, such as TNF-alpha, IL-6, IL-1beta and IFN-gamma by ELISA and qPCR analysis.	demethyleneberberine	0-3	interleukin 1 beta	Mus musculus	155-163
31931366-4	2020	DMB significantly inhibited the infiltration of CD4+ T cell and Kupffer cell as well as the expression of inflammatory cytokines, such as TNF-alpha, IL-6, IL-1beta and IFN-gamma by ELISA and qPCR analysis.	demethyleneberberine	0-3	interferon gamma	Mus musculus	168-177
31931366-5	2020	Western blotting analysis illustrated that DMB remarkably inhibited Con A-induced phosphorylation of IKK, IkappaB, NF-kappaB p65, ERK, JNK, p38 MAPK and STAT3 induced by Con A.	demethyleneberberine	43-46	v-rel reticuloendotheliosis viral oncogene homolog A (avian)	Mus musculus	125-128
31931366-5	2020	Western blotting analysis illustrated that DMB remarkably inhibited Con A-induced phosphorylation of IKK, IkappaB, NF-kappaB p65, ERK, JNK, p38 MAPK and STAT3 induced by Con A.	demethyleneberberine	43-46	mitogen-activated protein kinase 1	Mus musculus	130-133
31931366-5	2020	Western blotting analysis illustrated that DMB remarkably inhibited Con A-induced phosphorylation of IKK, IkappaB, NF-kappaB p65, ERK, JNK, p38 MAPK and STAT3 induced by Con A.	demethyleneberberine	43-46	mitogen-activated protein kinase 14	Mus musculus	140-143
31931366-5	2020	Western blotting analysis illustrated that DMB remarkably inhibited Con A-induced phosphorylation of IKK, IkappaB, NF-kappaB p65, ERK, JNK, p38 MAPK and STAT3 induced by Con A.	demethyleneberberine	43-46	mitogen-activated protein kinase 1	Mus musculus	144-148
31931366-5	2020	Western blotting analysis illustrated that DMB remarkably inhibited Con A-induced phosphorylation of IKK, IkappaB, NF-kappaB p65, ERK, JNK, p38 MAPK and STAT3 induced by Con A.	demethyleneberberine	43-46	signal transducer and activator of transcription 3	Mus musculus	153-158
31931366-7	2020	Taken together, our findings indicated that DMB could prevent Con A-induced AIH by regulating NF-kappaB and MAPK signaling, suggesting that DMB can serve as a promising candidate for therapy of AIH.	demethyleneberberine	44-47	mitogen-activated protein kinase 1	Mus musculus	108-112
31931366-7	2020	Taken together, our findings indicated that DMB could prevent Con A-induced AIH by regulating NF-kappaB and MAPK signaling, suggesting that DMB can serve as a promising candidate for therapy of AIH.	demethyleneberberine	140-143	mitogen-activated protein kinase 1	Mus musculus	108-112
31029761-8	2019	Inhibitory activities of demethyleneberberine, palmatine, berberine and timosaponin A-I were confirmed by an enzyme assay of COX-2, which validated the reliability of our approach.	demethyleneberberine	25-45	prostaglandin-endoperoxide synthase 2	Homo sapiens	125-130
27900412-7	2017	RESULTS: In vivo, DMB significantly alleviated the weight loss and diminished myeloperoxidase (MPO) activity, while significantly reduced the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha), and inhibited the activation of NF-kappaB signaling pathway.	demethyleneberberine	18-21	myeloperoxidase	Mus musculus	95-98
27900412-7	2017	RESULTS: In vivo, DMB significantly alleviated the weight loss and diminished myeloperoxidase (MPO) activity, while significantly reduced the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha), and inhibited the activation of NF-kappaB signaling pathway.	demethyleneberberine	18-21	interleukin 6	Mus musculus	192-210
27900412-7	2017	RESULTS: In vivo, DMB significantly alleviated the weight loss and diminished myeloperoxidase (MPO) activity, while significantly reduced the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha), and inhibited the activation of NF-kappaB signaling pathway.	demethyleneberberine	18-21	tumor necrosis factor	Mus musculus	215-242
27900412-7	2017	RESULTS: In vivo, DMB significantly alleviated the weight loss and diminished myeloperoxidase (MPO) activity, while significantly reduced the production of pro-inflammatory cytokines, such as interleukin (IL)-6 and tumor necrosis factor-alpha (TNF-alpha), and inhibited the activation of NF-kappaB signaling pathway.	demethyleneberberine	18-21	tumor necrosis factor	Mus musculus	244-253
27900412-8	2017	Furthermore, DMB decreased interferon (IFN)-gamma, increased IL-4 concentration in the mice splenocytes and the ratio of IgG1/IgG2a in the serum.	demethyleneberberine	13-16	interferon gamma	Mus musculus	27-49
27900412-8	2017	Furthermore, DMB decreased interferon (IFN)-gamma, increased IL-4 concentration in the mice splenocytes and the ratio of IgG1/IgG2a in the serum.	demethyleneberberine	13-16	interleukin 4	Mus musculus	61-65
27900412-8	2017	Furthermore, DMB decreased interferon (IFN)-gamma, increased IL-4 concentration in the mice splenocytes and the ratio of IgG1/IgG2a in the serum.	demethyleneberberine	13-16	LOC105243590	Mus musculus	121-125
27900412-8	2017	Furthermore, DMB decreased interferon (IFN)-gamma, increased IL-4 concentration in the mice splenocytes and the ratio of IgG1/IgG2a in the serum.	demethyleneberberine	13-16	immunoglobulin heavy variable V1-9	Mus musculus	126-131
26970305-7	2016	In addition, the remarkable oxidative damage and inflammation induced by NAFLD were both attenuated by DMB treatment, which is reflected by decreased lipid oxidative product, malonaldehyde (MDA) and inflammatory factors, tumor necrosis factor alpha (TNFalpha) and interleukin 1beta (IL-1beta).	demethyleneberberine	103-106	interleukin 1 beta	Mus musculus	264-281
26970305-7	2016	In addition, the remarkable oxidative damage and inflammation induced by NAFLD were both attenuated by DMB treatment, which is reflected by decreased lipid oxidative product, malonaldehyde (MDA) and inflammatory factors, tumor necrosis factor alpha (TNFalpha) and interleukin 1beta (IL-1beta).	demethyleneberberine	103-106	interleukin 1 beta	Mus musculus	283-291
25953522-5	2015	Demethyleneberberine was identified as the most abundant metabolite of CYP1A1- and CYP1B1-catalyzed oxidations, and thalifendine was generated at a relatively low rate.	demethyleneberberine	0-20	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	71-77
25953522-5	2015	Demethyleneberberine was identified as the most abundant metabolite of CYP1A1- and CYP1B1-catalyzed oxidations, and thalifendine was generated at a relatively low rate.	demethyleneberberine	0-20	cytochrome P450 family 1 subfamily B member 1	Homo sapiens	83-89
24321576-7	2014	Four metabolites of BBR, jatrorrhizine, columbamine, berberrubine and demethyleneberberine, were found to be able to up-regulate LDLR mRNA and protein expression.	demethyleneberberine	70-90	low density lipoprotein receptor	Homo sapiens	129-133
21963270-7	2012	The main water soluble monomeric product of berberine oxidation under physiological-near experimental conditions, OP1, was identified as demethyleneberberine cation (2,3-dihydroxy-9,10-dimethoxy-5,6-dihydroisoquinolino[3,2-a]isoquinolin-7-ium).	demethyleneberberine	137-157	bone morphogenetic protein 7	Homo sapiens	114-117
27376272-7	2016	Immunohistochemical (IHC) and quantitative polymerase chain reaction (qPCR) analysis indicated that DMB also has inhibitory effects on collagen synthesis and is able to increase collagen degradation by blocking the transforming growth factor beta 1 (TGF-beta1)-Smad signaling and reducing the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of MMP (TIMPs).	demethyleneberberine	100-103	transforming growth factor, beta 1	Mus musculus	215-248
27376272-7	2016	Immunohistochemical (IHC) and quantitative polymerase chain reaction (qPCR) analysis indicated that DMB also has inhibitory effects on collagen synthesis and is able to increase collagen degradation by blocking the transforming growth factor beta 1 (TGF-beta1)-Smad signaling and reducing the expression of matrix metalloproteinases (MMPs) and tissue inhibitors of MMP (TIMPs).	demethyleneberberine	100-103	transforming growth factor, beta 1	Mus musculus	250-259
26970305-7	2016	In addition, the remarkable oxidative damage and inflammation induced by NAFLD were both attenuated by DMB treatment, which is reflected by decreased lipid oxidative product, malonaldehyde (MDA) and inflammatory factors, tumor necrosis factor alpha (TNFalpha) and interleukin 1beta (IL-1beta).	demethyleneberberine	103-106	tumor necrosis factor	Mus musculus	221-248
26970305-7	2016	In addition, the remarkable oxidative damage and inflammation induced by NAFLD were both attenuated by DMB treatment, which is reflected by decreased lipid oxidative product, malonaldehyde (MDA) and inflammatory factors, tumor necrosis factor alpha (TNFalpha) and interleukin 1beta (IL-1beta).	demethyleneberberine	103-106	tumor necrosis factor	Mus musculus	250-258
25362106-8	2015	Moreover, we also found that DMB suppressed CYP2E1, hypoxia inducible factor alpha, and inducible nitric oxide synthase, which contributed to oxidative stress and restored sirtuin 1/AMP-activated protein kinase/peroxisome proliferator-activated receptor-gamma coactivator-1alpha pathway-associated fatty acid oxidation in chronic ethanol-fed mice, which in turn ameliorated lipid peroxidation and macrosteatosis in the liver.	demethyleneberberine	29-32	cytochrome P450, family 2, subfamily e, polypeptide 1	Mus musculus	44-50
25362106-8	2015	Moreover, we also found that DMB suppressed CYP2E1, hypoxia inducible factor alpha, and inducible nitric oxide synthase, which contributed to oxidative stress and restored sirtuin 1/AMP-activated protein kinase/peroxisome proliferator-activated receptor-gamma coactivator-1alpha pathway-associated fatty acid oxidation in chronic ethanol-fed mice, which in turn ameliorated lipid peroxidation and macrosteatosis in the liver.	demethyleneberberine	29-32	nitric oxide synthase 2, inducible	Mus musculus	52-119
25362106-8	2015	Moreover, we also found that DMB suppressed CYP2E1, hypoxia inducible factor alpha, and inducible nitric oxide synthase, which contributed to oxidative stress and restored sirtuin 1/AMP-activated protein kinase/peroxisome proliferator-activated receptor-gamma coactivator-1alpha pathway-associated fatty acid oxidation in chronic ethanol-fed mice, which in turn ameliorated lipid peroxidation and macrosteatosis in the liver.	demethyleneberberine	29-32	sirtuin 1	Mus musculus	172-181